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Abstract  
 The objective of the study was to investigate the sedative effects of medetomidine in 
combination with midazolam or butorphanol for routine imaging procedures. Eighty client 
owned dogs were recruited for the prospective, randomised, blinded clinical study. Dogs 
were randomly assigned to receive one of four treatments IM at time T0: 30 g/kg 
medetomidine (med30), 20 g/kg medetomidine combined with 0.3 mg/kg butorphanol 
(med20but0.3), 20 g/kg medetomidine combined with 0.3 mg/kg midazolam 
(med20mid0.3) and 10 g/kg medetomidine combined with 0.3 mg/kg midazolam 
(med10mid0.3).  The level of sedation was evaluated using a composite sedation scale 
assessed by one investigator (0=no sedation, 15=profound sedation).  The number of dogs 
that were deemed adequately clinically sedated and the dose of propofol administered as 
rescue sedation were recorded. Data are presented as mean ± standard deviation (SD). 
 
 Mean sedation scores at T30 in the groups that received med20but0.3 (9.8 ± 4) and 
med20mid0.3 (8.9 ± 4.4) were not statistically significantly different from each other but 
were significantly different to med10mid0.3 (5.6 ± 3.6). Only med20but0.3 was significantly 
associated with adequate clinical sedation while med10mid0.3 was associated with 85% 
sedation failure rate. The rescue sedation dose of propofol for the med10mid0.3 group (1.5 ± 
1 mg/kg) was significantly higher than the other treatments. A sedation score ≥10/15 was a 
satisfactory cut off to predict adequate clinical sedation.     
In healthy dogs, the combination of medetomidine with midazolam did not provide 
comparable sedation to the same dose of medetomidine in combination with butorphanol in a 
clinical setting.  
 
Keywords: Sedation; Dog; Midazolam; Medetomidine; Butorphanol; Imaging 
  
 Introduction  1 
 Sedation of small animals is a daily occurrence in veterinary practice. To perform 2 
procedures such as imaging, deep sedation, defined as patients being immobile and 3 
unresponsive to external stimuli, is usually required (Koroglu et al., 2005; Murrell, 2016). In 4 
healthy companion animals, alpha-2 adrenoreceptor agonists, such as medetomidine are the 5 
most commonly used sedatives in the UK (Brodbelt et al., 2008). Medetomidine provides 6 
reliable and profound sedation which can be rapidly reversed with atipamezole  ( Pypendop 7 
and Verstegen, 1998; Murrell, 2016). However, alpha-2 adrenoreceptor agonists also have 8 
severe cardiovascular consequences such as peripheral vasoconstriction, marked bradycardia 9 
and decreased cardiac output (Kojima et al., 2002; Murrell and Hellebrekers, 2005).  10 
Medetomidine can be effectively combined with opioid agents such as butorphanol to provide 11 
the same level of sedation while requiring lower doses of alpha-2 adrenoreceptor agonists.  In 12 
dogs, the combination of medetomidine with butorphanol is widely reported in the literature 13 
and this combination is licensed for canine sedation in the UK. Compared to medetomidine 14 
alone, the addition of butorphanol provides a quicker onset, and more profound sedation 15 
whilst using lower doses of medetomidine ( Muir et al., 1999; Girard et al., 2010).  16 
Benzodiazepines may also be a potential alternative agent for combination with 17 
medetomidine in place of opioids. Midazolam is well absorbed intramuscularly and has 18 
minimal cardiovascular effects ( Schwartz et al., 2013; Hopkins et al., 2014). While in human 19 
medicine, midazolam is the most commonly used sedativea and is effective (Godwin et al., 20 
2014), in veterinary medicine it is rarely used alone or in combination in healthy dogs. When 21 
administered as a single agent it provides minimal or no sedation in healthy dogs (Court and 22 
Greenblatt, 1992). However, a few experimental studies have suggested that when midazolam 23 
when combined with medetomidine, sedation was much improved compared to 24 
medetomidine alone (Hayashi et al., 1994; Kojima et al., 1999). Additionally, Hayashi et al. 25 
  
(1994) reported the combination to be comparable or even superior with better muscle 26 
relaxation to the combination of medetomidine with butorphanol in dogs (Hayashi et al., 27 
1994; Kojima et al., 1999).  28 
 The present study evaluated the effect of medetomidine in combination with 29 
butorphanol compared with midazolam by using a sedation scoring system, recording the 30 
number of dogs reaching clinical sedation, the rate of sedation failures and the dose 31 
requirement for rescue sedation with propofol. It was hypothesized that the sedative effect of 32 
medetomidine in combination with midazolam would be similar to the sedative effect of 33 
medetomidine and butorphanol. 34 
Materials and methods  35 
Animals  36 
The study protocol was approved by the Bristol University Animal Ethical Review 37 
Committee on the 24th of September 2015 (VIN/15/003) and informed owner consent was 38 
obtained for all dogs that were enrolled on the study. The study was also conducted under an 39 
Animal Test Certificate (42273/002) and complied with Good Clinical Practice standards. 40 
Eighty client-owned dogs scheduled for elective diagnostic imaging procedures at a 41 
University hospital were recruited.  All animals were healthy based on full clinical 42 
examination and were classified as American Society of Anesthesiologists (ASA) I or II, had 43 
no or mild pain at presentation and weighed between 10 and 40 kg. One investigator collected 44 
all the data and was unaware of treatment allocation.  45 
Study design and treatments  46 
The dogs were randomly assigned to receive one of the four sedation treatments. 47 
Randomisation was performed by block by a random number generator using Excel 48 
  
Microsoft Formulas (Microsoft Software 2014) depending on body weight (10-25kg 49 
SSMALL and 26-40kg SLARGE) in the four treatment groups: the positive control: 20 g/kg 50 
medetomidine with 0.3 mg/kg butorphanol (med20but0.3), the negative control : 30 g/kg 51 
medetomidine (med30), 20 g/kg medetomidine with 0.3 mg/kg midazolam (med20mid0.3) 52 
and 10 g/kg medetomidine with 0.3 mg/kg midazolam (med10mid0.3).  53 
 The treatment administrator was a registered nurse or veterinary surgeon. The 54 
allocation sheet was enclosed in an opaque sealed envelope. The veterinary surgeon involved 55 
in the randomization process and the treatment administrators were not involved in the data 56 
collection. All drugs, medetomidine (1 mg/mL, Sedastart, Animal Care Limited), butorphanol 57 
(10 mg/mL, Alvegesic, Dechra Veterinary Products), midazolam (5 mg/mL, Dormazelam, 58 
Regivet BV) and atipamezole (5 mg/mL, Sedastop, Animal Care Limited) were administered 59 
into the lumbar muscles using a 25mm long needle and an appropriate sized syringe for the 60 
set volume. When two drugs were used for sedation they were injected separately into the left 61 
and right lumbar muscles because there are no data on the compatibility of these drugs when 62 
mixed in the same syringe.  63 
Experimental protocol  64 
 Once recruited, the dogs were taken in the recovery room. This is the designated area 65 
for animals to be recovered from anaesthesia and is a quieter area compared with the main 66 
dog wards. A baseline heart rate (HR), respiratory rate (RR), body temperature (BT), sedation 67 
score and body condition score (BCS) and pain score using a simple descriptive scale were 68 
collected (Appendix: Supplementary table 2). An intravenous catheter was placed in the 69 
cephalic vein prior to sedative administration. The time of sedative drug administration was 70 
Time = 0 (T0).   71 
  
Assessment of sedation  72 
Sedation was scored using a composite descriptive scale described by Raszplewicz et 73 
al. (2003) and Gurney et al. (2009) (Appendix: Supplementary table 1) (Raszplewicz et al., 74 
2013).  75 
Sedation was scored during the initial clinical examination of the dog. Following the 76 
test drug administration (T=0), sedation was scored every 5 min until T20, then every 10 min 77 
until atipamezole administration (at T60 min). The time of peak sedation was considered to 78 
occur at T30.  79 
Rescue sedation and treatment failure 80 
Adequacy of sedation was assessed by the investigator. Sedation was deemed 81 
inadequate if the dog did not assume spontaneous lateral recumbency within 40 minutes of 82 
the test drug administration and was still responsive to stimulation (such as moving the dog to 83 
the trolley to be moved to imaging) at this time point. The data from these dogs were 84 
recorded as a treatment failure. If the dog was sufficiently sedated to be moved to imaging, 85 
but then not sufficiently sedated to allow imaging, propofol was administered IV to effect in 86 
1 mg/kg aliquots and the dose recorded. If a dog required rescue propofol during imaging it 87 
was also counted as a treatment failure.  88 
 Time to imaging   89 
The time that imaging started and finished was recorded. It was assumed that time to 90 
imaging was the time it took to achieve adequate sedation for imaging from drug 91 
administration.  92 
  
Monitoring of physiological variables  93 
During the procedure, HR and RR were measured manually by palpating the femoral 94 
pulse and by visually observing respiration over a 15-s period. This was done immediately 95 
before the sedation score was measured to avoid an artificial increase in HR and RR caused 96 
by the manipulation of the patient for the sedation score. 97 
Monitoring of adverse events  98 
Any adverse events that occurred during the study were recorded.  99 
 100 
Statistical analysis  101 
A power calculation to determine sample size was based on a study by Kuusela et al. 102 
(2000) using the same composite sedation scoring system (Kuusela et al., 2000). They 103 
indicated that 17 dogs per group were needed for a statistical power of 90% to detect a 104 
difference in sedation scores of 25% with an alpha error of 0.05. Therefore, it was decided to 105 
recruit 20 dogs/ group in the present investigation. 106 
Data were assessed for normality and homocedasticity of variance using Shapiro-Wilk 107 
test and distribution. A one way between groups analysis of variance (ANOVA) was used to 108 
compare sedation score at T30, rescue sedation dose and time to imaging.  A mixed between-109 
within ANOVA was used to compare sedation scores, HR, RR and BT over time. Wilks’ 110 
lambda was used to assess interaction between factors and Partial Eta Squared to examine its 111 
effect size.  112 
A Chi-square test was used to compare the number of dogs per treatment group that 113 
were clinically sedated, were treatment failures and adverse event incidence. When post-hoc 114 
testing was carried out, the P value at 0.05 was adjusted by Bonferroni correction P/n 115 
  
(Beasley and Schumacker, 1995). Non-parametric data (age, body condition score: BCS, pain 116 
level of the dog before sedation) were assessed using Kruskal Wallis analysis of variance.  P 117 
values < 0.05 were considered statistically significant apart from when a Bonferroni 118 
correction was applied.  Data were analysed using SPSS 18 (IBM, NY,USA).  119 
Ancillary analyses were performed to determine a clinically relevant cut off score for 120 
the sedation scoring system used in this study. The aim was to find a reliable cut off score 121 
that was sensitive enough to identify the proportion of dogs that were clinically sedated from 122 
the ones that were not. To determine the sensitivity and specificity and the appropriate cut-off 123 
score of the sedation scoring system, receiver operating characteristic curve (ROC) and two-124 
by-two tables to determine the sensitivity, specificity positive predictive value and negative 125 
predictive value were performed (Hanley and Mcneil, 1982; Abdul Ghaaliq Lalkhen, 2008).  126 
Normally distributed data are presented as mean ± standard deviation (SD).127 
  
Results  128 
Demographic data from the four groups are shown in table 1. There were no 129 
significant differences in age, body weight, sex distribution, BCS and pain scores between the 130 
treatment groups. There was no association between treatment groups and imaging 131 
procedures, either radiography or computed tomography (X2, p=0.37). The imaging 132 
comprised 41 radiographic procedures and 39 CT procedures. There were no significant 133 
differences in the duration of imaging between the treatment groups with a mean time of (24 134 
± 15) min (P=0.18). 135 
Of the eighty dogs recruited to the study all the dogs were included in analysis of 136 
sedation scores over time, sedation scores at T30, sedation failure rate and rescue sedation 137 
dose of propofol. The sedation scores over the first 30 min changed significantly with time, 138 
increasing after treatment administration in all the groups (P<0.005). There was not a 139 
statistical difference between the treatment groups in terms of sedation score over the first 30 140 
min of data collection (P=0.94) (figure 1). At T30 there was a significant difference in 141 
sedation score between the treatment groups (P=0.006). Numerically the sedation scores in 142 
the med20mid0.3 (8.9 ± 4.4) and med20but0.3 (9.8 ± 4) groups were greater than the med30 143 
(7.5 ± 2.7), however med30 was not statistically significant from med20but0.3 or 144 
med20mid0.3. Med10mid0.3 (5.6 ± 3.6) had the lowest sedation score and was significantly 145 
different from med30, med20but0.3 and med20mid0.3 (figure 2) (table 2). 146 
In this study, 46 (57.5%) of all dogs were considered as sedation failures. There was a 147 
significant association between treatment group and failure rate (P=0.001). Dogs in the 148 
Med20but0.3 group were significantly less likely to be a treatment failure and accounted for 149 
only 22% of the treatment failures, while dogs in the med10mid0.3 group were significantly 150 
more likely to be treatment failures with 85% of cases being sedation failures (see table 2).  151 
  
The amount of rescue sedation (propofol dose) did significantly differ between the 152 
treatment groups (P=0.001). Med30 (0.9 ± 0.6 mg/kg propofol) was not statistically 153 
significantly different from the other treatments. Med20but0.3 (0.4 ± 0.7 mg/kg) and 154 
med20mid0.3 (0.7 ± 0.9 mg/kg) were not statistically different from each other but were 155 
statistically significantly different to med10mid0.3 (1.5 ± 1 mg/kg), with a higher dose of 156 
propofol required in the med10mid0.3 group (table 2). 157 
Physiological variables  158 
Heart rate, RR, and BT remained within a normal clinical range in all dogs during the 159 
study. Heart rate and RR decreased significantly over time (P<0.005). There was not a 160 
statistically significant difference between treatments for the physiological variables HR 161 
(P=0.4), RR (P=0.26) and BT (P=0.6). The med10mid0.3 group had a trend for having less 162 
marked effects on the HR and RR over time.  163 
Sedation scoring assessment 164 
Based on clinical judgement two cut off scores, 10/15 and 11/15, were analysed. 165 
When all dogs were considered together the range of sedation scores at T30 was to 1-14 with 166 
a mean score of 7.95 ± 4. The cut off sedation score of 11/15 resulted in high sensitivity 98 % 167 
(dogs identified as being appropriately clinically sedated). The specificity (dogs identified as 168 
not being suitability sedated) was suboptimal at 65% with AUC of the ROC of 0.8. The area 169 
under the ROC curve characterises the general accuracy of a test. When the value approaches 170 
one it shows a high sensitivity and specificity (Abdul Ghaaliq Lalkhen, 2008).  A 10/15 171 
sedation score cut-off was more appropriate with a slightly lower sensitivity of 95.5% and 172 
improved specificity of 85% with a higher AUC of the ROC of 0.9. An AUC of >0.9 is 173 
classed as an excellent test (table 3).  174 
 175 
  
Adverse events 176 
 177 
Seventeen dogs experienced an adverse event during the study (table 4). There was no 178 
significant association between the treatment groups and adverse events (p=0.06). 179 
Discussion  180 
 The aim of this study was to evaluate whether the intramuscular combination of 181 
medetomidine and midazolam provided similar sedation to a standard butorphanol and 182 
medetomidine combination in a clinical setting for sedation for imaging procedures. Once all 183 
the measured variables were assessed together, the combination of medetomidine and 184 
midazolam, at the doses investigated, did not provide consistent evidence that it was a reliable 185 
and adequate sedative.  186 
 At T30, there was no difference in sedation scores between med20but0.3 and 187 
med20mid0.3. However, in our study, adequate clinical sedation was only achieved and 188 
associated with the combination of med20but0.3. An explanation for the discrepancy between 189 
sedation score and clinical sedation in the present study may be that the criteria used in the 190 
sedation scoring system may not uniquely measure sedation, resulting in high sedation scores 191 
for med20mid0.3 compared to med20but0.3 although the plane of sedation was actually 192 
different. Midazolam alone causes rapid and profound muscle relaxation (Adams et al., 1985; 193 
Court and Greenblatt, 1992). By comparison, medetomidine causes dose-dependent sedation 194 
associated with loss of posture and reduced consciousness (Kuusela et al., 2000) Although the 195 
sedation scoring system used in the present study was created to evaluate alpha-2 196 
adrenoreceptor agonists sedation, it may not be adequate when assessing a combination of 197 
midazolam with the alpha-2 adrenoreceptor agonist. The muscle relaxation may have not only 198 
impacted posture scoring but also other dynamic behavioural endpoints such as resistance to 199 
lateral recumbency, response to noise and general appearance.   200 
  
At T30, sedation scores in the med10mid0.3 group were significantly lower than the 201 
other treatments suggesting that this combination achieved only mild sedation. It has been 202 
reported that dogs administered medetomidine at 10 µg/kg intramuscularly are still alert and 203 
responsive (Hammond et England, 1994). The addition of midazolam did not seem to provide 204 
further deepening of sedation in the study. Our observations are supported by Canfrán et al. 205 
(2016). Using the same sedation scoring system as the one used in the present study they 206 
reported a median score of 8 with 5 g/kg dexmedetomidine and 0.3 mg/kg midazolam which 207 
was not significantly different from dexmedetomidine alone. Compared to the experimental 208 
Canfrán et al. (2016) study, our sedation score was much lower with med20mid0.3. The 209 
difference may be caused by the ‘controlled environment’ of the Canfrán et al. (2016) study 210 
as veterinary hospitals are stressful environments for dogs and anxious dogs are less likely to 211 
sedate (Riviere et Papich, 2009; Canfrán et al., 2016;).  212 
Initially the positive control for the study was 10 µg/kg of medetomidine and 0.1 213 
mg/kg of butorphanol and medetomidine 30 µg/kg was the negative control. However, due to 214 
the high sedation failure rate in the initial phase of the study of the positive control the doses 215 
of both drugs were increased. A high failure rate meant that the investigator was frequently 216 
assessing dogs for 40 min, which was delaying the routine of the hospital. The difference in 217 
medetomidine dose between the treatment groups and the negative control is a limitation of 218 
the study as it makes comparisons between treatment groups challenging.  Furthermore, the 219 
higher dose of butorphanol was out of the summary of product characteristics (SPC) ‘sedative 220 
dose range’ and was in the ‘analgesic dose range’. Therefore, some of the additional sedative 221 
effects of the positive control may have been related to better analgesia especially during 222 
positioning of the dog for imaging. The population of dogs in the study were recruited from 223 
the orthopaedic department with an over representation of middle-aged dogs. The pain level 224 
was assessed before recruitment and only non-painful or mildly painful dogs were included in 225 
  
the study. However, all of the dogs in the study were suffering from or had suffered to some 226 
degree with an orthopaedic issue. As such, manipulation of the limbs may have been more 227 
painful than in ‘normal’ dogs. Invasiveness of the imaging procedure was not scored, 228 
although the diagnostic imaging procedures were balanced between the treatment groups. If a 229 
lower dose of butorphanol had been used, as was originally proposed, it is possible that the 230 
positive control might not have been associated with sedation success compared to the 231 
midazolam combinations.  232 
Using sedation scores as a primary outcome measure is challenging especially in a 233 
clinical setting where it is difficult to control multiple variables. This study has revealed the 234 
importance of incorporating into the design, the outcome of the sedation and failure rates, 235 
when assessed in a clinical setting. This will provide more reliable and clinically convincing 236 
results of the potency of sedatives in future studies.  237 
 238 
Conclusion 239 
This study highlights the importance of assessing adequacy of sedation for a procedure 240 
as an outcome measure especially in a clinical environment. This is particularly relevant when 241 
transferring results to clinical practice. Our initial hypothesis that medetomidine-midazolam 242 
would provide adequate sedation comparable to medetomidine-butorphanol was not 243 
supported. Although the study suggests similar planes of sedation, medetomidine-midazolam 244 
was not an adequate combination for sedation for routine procedures requiring profound 245 
sedation. Furthermore, the study also demonstrated that lower doses of medetomidine with 246 
midazolam provided poor sedation associated with a high failure rate and a high dose 247 
requirement for rescue sedation medication.  248 
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Table 1 324 
Characteristics of dogs for all treatment groups.  325 
Treatments 
Age (years, 
months) 
Weight 
(kg) 
Body condition 
score (/9) 
M:MN:F:FN 
Pain 
scores 
total 
Med30 5 [10] 
25.6 ± 
7.6 
5.5 [4] 2:5:6:7 
0 [1] 
20 
Med20but0.3 3.9 [7.6] 24.4 ± 8 5 [4] 2:5:4:7 
0 [1] 
18 
Med20mid0.3 4 [7.3]  24.3 ± 7 5 [5] 4:6:6:6 
0 [1] 
22 
Med10mid0.3 3.5 [7.3] 25 ± 7.7 5.5 [5] 3:6:8:3 
0 [1] 
20 
All dogs 4 [10.6] 
24.8 ± 
7.7 
5 [6] 24:23:11:22 
0 [1] 
80 
Data are presented as mean ± (standard deviation) SD or median [range], age in years and 326 
months, body weight in kg, body condition score (/9), sex distribution with number of dogs. 327 
M:MN:F:FN : Male:MaleNeutered:Female:FemaleNeutered, pain as a score (0-3 ; 0 no pain, 328 
3 severe pain) n=80. 329 
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Table 2  330 
Sedation scores at T30 (30 min after administration of the test drug(s)), propofol dose 331 
required for rescue sedation and rate of sedation failure for dogs treated with 30 g/kg 332 
medetomidine (med30), 20 g/kg medetomidine with 0.3 mg/kg butorphanol (med20but0.3), 333 
20 g/kg medetomidine with 0.3 mg/kg midazolam (med20mid0.3) and 10 g/kg 334 
medetomidine with 0.3 mg/kg midazolam (med10mid0.3).  335 
 Sedation score at 
T30 
Rescue sedation dose of 
propofol 
Sedation failure 
rate 
Med30 7.5  ± 2.7# 0.9 ± 0.6 80% 
Med20but0.3 9.8 ± 4
# 0.4 ± 0.7 22%* 
Med20mid0.3 8.9 ± 4.4
# 0.7 ± 0.9 54% 
Med10mid0.3 5.6 ± 3.6 1.5 ± 1 85%* 
Data are presented as Mean ± standard deviation (SD) or  % . # values differ significantly 336 
(P<0.05) from med10mid0.3, * statistically significantly different from each other at P<0.05, 337 
n=80. 338 
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Table 3.  339 
Sensitivity and specificity of the sedation scoring system for assessing clinical sedation . 340 
Sedation score cut-off (/15) ≤10 ≤11 
Sensitivity 95.5% 98% 
Specificity 85% 65% 
Positive predictive value 90% 79% 
Negative predictive value 93.5% 95.5% 
AUC, 95% CI 0.9, 0.8-1 0.8, 0.7-0.9 
AUC, area under the curve; CI, confidence interval 341 
  342 
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Table 4  343 
Adverse events for all treatment groups.. 344 
 345 
 Vomiting 
Prolonged 
recovery 
Myoclonic 
episode 
Paradoxical 
behaviour 
Med30 2 0 0 1 
Med20but0.3 0 2 0 0 
Med20mid0.3 3 0 0 2 
Med10mid0.3 1 0 1 5 
All dogs 6 2 1 8 
Data presented as number of dogs, n=80. Paradoxical behaviours :Defined as 346 
agitation,excitation, vocalisation and sound hypersensitivity. Myoclonic episode: Following 347 
propofol administration 348 
 349 
350 
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 Figure 1. 351 
 Sedation scores over time for all treatments.  352 
 353 
Data are presented as mean ± SE and time in min, n=80  354 
  355 
356 
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Figure 2. 357 
 Sedation scores at T30 for all treatments.  358 
 359 
Data presented as box and whisker plots *values differ significantly (P<0.05) between 360 
med10mid0.3 and med30; # values differ significantly (P<0.05) between med10mid0.3 and 361 
med20but0.3 and med20mid0.3; § values differ significantly (P<0.05) between med30 and 362 
med10mid0.3, n=80. 363 
 364 
 365 
 366 
 367 
 368 
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Appendix: 369 
Supplementary table 1 370 
Composite simple descriptive sedation score described by Raszplewicz et al. (2003) and 371 
Gurney et al. (2009). 372 
Criteria Descriptor Score 
Spontaneous posture Standing 0 
 Sternally recumbent 1 
 Laterally recumbent 2 
Palpebral reflex Brisk 0 
 Slow 1 
 Absent 2 
Eye position Forward 0 
 Rotated ventrally 2 
Respond to sound (handclap) Body movement 0 
 Head movement 1 
 Ear twitch 2 
 No reaction 3 
Resistance to lateral recumbency Full (stands) 0 
 Moderate restraint required 1 
 Mild restraint required 2 
 No resistance 3 
Overall appearance No sedation apparent 0 
 Mild sedation 1 
 Moderate sedation 2 
 Well sedated 3 
Total possible sedation score  15 
 373 
 374 
 375 
 376 
 377 
 378 
 379 
 380 
  381 
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Supplementary table 2  382 
 383 
Simple descriptive scale (SDS) used to grade pain level 384 
 385 
Descriptor Score 
No pain 0 
Mild pain 1 
Moderate pain 2 
Severe pain 3 
 386 
 387 
 388 
 389 
 390 
